AbbVie Cuts Full-Year EPS Guidance as $10.9 Billion Apogee Therapeutics Deal Dilutes Near-Term Earnings

AbbVie lowered its full-year earnings per share guidance following the announced $10.9 billion acquisition of Apogee Therapeutics, as integration costs and deal financing charges introduce near-term EPS dilution even as the company's core immunology franchise demonstrated solid Q2 performance.

• AbbVie reduced full-year EPS guidance to account for acquisition costs and financing charges from the $10.9 billion Apogee Therapeutics deal
• Q2 adjusted EPS of $3.65 beat estimates, but the guidance cut overshadowed the operational beat in investor focus during the earnings call
• Apogee's bispecific antibody pipeline targets atopic dermatitis and autoimmune indications, diversifying AbbVie's revenue base beyond Skyrizi and Rinvoq

AbbVie's full-year EPS guidance reduction stems directly from the accounting impact of its $10.9 billion Apogee Therapeutics acquisition. Integration costs, deal financing charges, and purchase accounting adjustments—standard mechanics of large pharma acquisitions—typically weigh on reported earnings in the first year post-close while providing minimal offsetting revenue contribution during the integration period.

The guidance cut arrives despite a strong operational quarter: Q2 adjusted EPS of $3.65 beat analyst estimates, reflecting the continuing commercial momentum of Skyrizi in psoriasis/IBD and Rinvoq in rheumatoid arthritis and other autoimmune indications. The market's typical reaction to this pattern—earnings beat plus guidance cut—can be mixed, requiring investors to assess whether near-term dilution is justified by long-term pipeline value.

Apogee's bispecific antibody assets target atopic dermatitis and related autoimmune conditions, areas where AbbVie already has established market share. The strategic logic centers on next-generation mechanisms that could extend the immunology franchise's revenue run well beyond current patent cliffs. For ABBV investors, the key variable is how quickly Apogee's pipeline can generate post-launch revenue sufficient to restore EPS guidance trajectory within 18-24 months of deal close.

Source: GuruFocus | 1 source